COPD: Journal of Chronic Obstructive Pulmonary Disease

Pipeline Review for Chronic Obstructive Pulmonary Disease (COPD) - H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 19, 2020
Health, Pharmaceutical, Medicine, Clinical medicine, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease, Pulmonology, Respiratory therapy, Pulmonary disease, chronic obstructive, severe early-onset, Respiratory compromise

The "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.

Sunrise Medical Management Offers HGE Health's Remote Symptom Management Platform to Respiratory Patients

Retrieved on: 
Tuesday, August 18, 2020
Health, Articles, Respiratory disease, Chronic obstructive pulmonary disease, Health care, Chronic condition, HGE, COPD: Journal of Chronic Obstructive Pulmonary Disease

FT. WASHINGTON, Pa., Aug. 18, 2020 /PRNewswire-PRWeb/ --Sunrise Medical Management LLC ("Sunrise") has selected HGE Health's remote symptom management platform, HGE Care, to offer remote patient monitoring services to patients with Chronic Obstructive Pulmonary Disease (COPD) throughout its Arizona network.

Key Points: 
  • FT. WASHINGTON, Pa., Aug. 18, 2020 /PRNewswire-PRWeb/ --Sunrise Medical Management LLC ("Sunrise") has selected HGE Health's remote symptom management platform, HGE Care, to offer remote patient monitoring services to patients with Chronic Obstructive Pulmonary Disease (COPD) throughout its Arizona network.
  • Patients enrolled in the HGE Care platform submit their respiratory symptoms on a daily basis using a mobile application.
  • The HGE Care platform is available to healthcare providers such as Sunrise as a turnkey solution.
  • Michael J. Markus, CEO of HGE Health, views Sunrise as an ideal partner for enrolling patients in HGE Care.

Zhongchao Inc. Develops Live Interactive Courses Promoting the Global Initiative for Chronic Obstructive Lung Disease

Retrieved on: 
Tuesday, August 11, 2020
Health, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Gold, Respiratory disease, Medicine, Clinical medicine, Respiratory therapy, COPD Awareness Month

Launched in 1997 in collaboration with the National Heart, Lung, and Blood Institute of U.S. National Institutes of Health and the World Health Organization , GOLD is a global initiative to raise awareness of chronic obstructive pulmonary disease ("COPD") and to improve prevention and treatment of this lung disease for patients around the world.

Key Points: 
  • Launched in 1997 in collaboration with the National Heart, Lung, and Blood Institute of U.S. National Institutes of Health and the World Health Organization , GOLD is a global initiative to raise awareness of chronic obstructive pulmonary disease ("COPD") and to improve prevention and treatment of this lung disease for patients around the world.
  • The Project decomposes the guidelines covered in the latest GOLD Report (2020 Edition) and converts them into scene-based, live interactive programs/courses.
  • The Project is a result of the close collaboration between Zhongchao and CAHPE along with the deep involvement of many subject experts.
  • The Company undertakes no obligation to publicly revise these forwardlooking statements to reflect events or circumstances that arise after the date hereof.

miRagen to Host a Key Opinion Leader Call on Idiopathic Pulmonary Fibrosis on Tuesday, June 23rd

Retrieved on: 
Tuesday, June 16, 2020
Medical specialties, Pulmonology, Medicine, Respiratory diseases, Lung transplantation, Organ transplantation, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease, Interstitial lung disease, Forward-looking statement, Lung, Chronic obstructive pulmonary disease

Dr. Martinezs interests include chronic obstructive pulmonary disease (COPD), interstitial lung disease, lung transplantation, and lung volume reduction.

Key Points: 
  • Dr. Martinezs interests include chronic obstructive pulmonary disease (COPD), interstitial lung disease, lung transplantation, and lung volume reduction.
  • Ms. Barnes is a research advocate who is an ally for patients suffering from lung and fibrotic diseases.
  • miRagen undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law.
  • Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Retrieved on: 
Monday, June 8, 2020
Respiratory diseases, Pulmonology, Medicine, Chronic lower respiratory diseases, Respiratory therapy, Chronic obstructive pulmonary disease, Targeted lung denervation, Obstructive lung disease, Denervation, Acute exacerbation of chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Respiratory disease

MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • MINNEAPOLIS, June 8, 2020 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA).
  • Nuvaira's lung denervation system is designed to reduce the risk of moderate-to-severe COPD exacerbations in patients on optimal medical care.
  • Nuvaira also announces appointment of Tim Herbert, President & CEO of Minneapolis-based Inspire Medical Systems to its Board of Directors.
  • Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/nuvaira-announces-fda-breakthrou...

Biomarck Pharmaceuticals to Present Expanded Analysis of BIO-11006 Clinical Data in Treatment of Non-Small Cell Lung Cancer at the American Thoracic Society 2020 International Conference

Retrieved on: 
Monday, June 1, 2020
Oncology, Health, Environment, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Respiratory diseases, Pulmonology, Medical specialties, Acute respiratory distress syndrome, Intensive care medicine, Respiratory physiology, Respiratory disease, Chronic obstructive pulmonary disease, Lung, COPD: Journal of Chronic Obstructive Pulmonary Disease, BIO-11006, Biomarck Pharmaceuticals, Ltd.

BIO-11006 appears to have a unique mechanism of action in blocking inflammation and cytokine production in the lungs of patients, said Professor Adler.

Key Points: 
  • BIO-11006 appears to have a unique mechanism of action in blocking inflammation and cytokine production in the lungs of patients, said Professor Adler.
  • Inflammation and the cytokine storm are well known as a major contributor to ARDS.
  • BIO-11006 is being investigated for the treatment of ARDS, Chronic Obstructive Pulmonary Disease ( COPD ) and Non-Small Cell Lung Cancer (NSCLC).
  • Biomarck is a biopharmaceutical company focused on the development of drugs to treat ARDS, COPD, cancer and other hard to treat diseases.

Deborah Heart and Lung Center Introduces Remote Patient Monitoring for COPD Patients

Retrieved on: 
Tuesday, May 26, 2020
Pulmonology, Chronic lower respiratory diseases, Health, Respiratory disease, Chronic obstructive pulmonary disease, Deborah Heart and Lung Center, COPD: Journal of Chronic Obstructive Pulmonary Disease, Organ systems, Obstructive lung disease, COPD Awareness Month

BROWNS MILLS, N.J., May 26, 2020 /PRNewswire-PRWeb/ --Deborah Heart and Lung Center, New Jersey's only specialty heart, lung, and vascular hospital, and an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute, has announced the introduction of remote patient monitoring for patients diagnosed with chronic obstructive pulmonary disease (COPD).

Key Points: 
  • BROWNS MILLS, N.J., May 26, 2020 /PRNewswire-PRWeb/ --Deborah Heart and Lung Center, New Jersey's only specialty heart, lung, and vascular hospital, and an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute, has announced the introduction of remote patient monitoring for patients diagnosed with chronic obstructive pulmonary disease (COPD).
  • Patients diagnosed with COPD require physician monitoring to prevent the disease from progressing.
  • With the expansion of telemedicine and remote monitoring services prompted by the Coronavirus epidemic, Deborah has instituted a new remote patient monitoring services platform.
  • Called HGE Care the remote monitoring platform is designed for COPD patients who have been discharged from the hospital and are recuperating at home.

Global Ventilator Market Report 2020-2025: Featuring Profiles of Key Players Medtronic, Zoll Medical, Getinge AB, Allied Healthcare Products and Air Liquide

Retrieved on: 
Friday, May 22, 2020
Medicine, Pulmonology, Health, Respiratory diseases, Respiratory disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, Chronic condition

DUBLIN, May 22, 2020 /PRNewswire/ -- The "Ventilator Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 22, 2020 /PRNewswire/ -- The "Ventilator Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The ventilator market is projected to grow at a CAGR of 5.53% to reach US$3,095.180 million by 2025 from US$2,240.940 million in 2019.
  • The rise in cases of respiratory emergencies and Chronic Obstructive Pulmonary Disease (COPD) are the major factors, which are strengthening the growth of global ventilator market.
  • The "Ventilator Market - Forecasts from 2020 to 2025" report segments the industry as follows:

Global Ventilator Market 2020: Innovation is Key to Meet Surge in Demand from COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 21, 2020
Medical devices, Health, Pulmonology, Respiratory diseases, Medicine, Health, Respiratory disease, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease

The ventilator market is projected to grow at a CAGR of 5.53% to reach US$3,095.180 million by 2025 from US$2,240.940 million in 2019.

Key Points: 
  • The ventilator market is projected to grow at a CAGR of 5.53% to reach US$3,095.180 million by 2025 from US$2,240.940 million in 2019.
  • The rise in cases of respiratory emergencies and Chronic Obstructive Pulmonary Disease (COPD) are the major factors, which are strengthening the growth of global ventilator market.
  • For example in light of the global pandemic that has gripped our planet and the impact that has permeated every aspect of human, innovation has been key.
  • The "Ventilator Market - Forecasts from 2020 to 2025" report segments the industry as follows:

Global Breath Analyzer Markets, 2020-2025 - Rising Demand for Effective Diagnosis of Cancer and Other Diseases is Boosting Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 5, 2020
Medical devices, Health, Chronic lower respiratory diseases, Pulmonology, Medicine, Health, Respiratory therapy, Health effects of tobacco, Respiratory disease, Chronic obstructive pulmonary disease, Asthma, Chronic condition, COPD: Journal of Chronic Obstructive Pulmonary Disease, Lung

The "Breath Analyzer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breath Analyzer Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global breath analyzer market is currently witnessing robust growth.
  • Furthermore, the rising demand for effective diagnosis of cancer and other diseases, including asthma and chronic obstructive pulmonary disease (COPD), is also providing a boost to the market growth.
  • How has the global breath analyzer market performed so far and how will it perform in the coming years?